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Abstract
Purpose:Metastasis to adrenal gland from lung, breast, and kidney malignancies are quite common. Historically radiotherapy was
intended for pain palliation. Recent studies with stereotactic body radiotherapy (SBRT) including Cyberknife robotic radiosur-
gery aiming at disease control brings about encouraging results. Here we represent the early clinical experience with Cyberknife
stereotactic system from an Indian cancer care center. The main purpose of this retrospective review is to serve as a stepping stone
for future prospective studies with non- invasive yet effective technique compared to surgery. Methods: We retrospectively
reviewed four cases of adrenal metastases (three: lung and one: renal cell carcinoma) treated with Cyberknife SBRT. X sight spine
tracking was employed for planning and treatment delivery. Patients were evaluated for local response clinically as well as with
PETCT based response criteria. Results:With a median gross tumor volume of 20.5 cc and median dose per fraction of 10 Gy, two
patients had complete response (CR) and two had partial response (PR) when assessed 8-12 weeks post treatment as per RECIST.
There was no RTOG grade 2 or more acute adverse events and organs at risk dosage were acceptable. Till last follow up all the
patients were locally controlled and alive. Conclusion: Cyberknife SBRT with its unique advantages like non- invasive, short
duration outpatient treatment technique culminating in similar local control rates in comparison to surgery is an attractive op-
tion. World literature of linear accelerator based SBRT and our data with Cyberknife SBRT with small sample size and early
follow up are similar in terms of local control in adrenal metastases. Future prospective data would reveal more information on
the management of adrenal metastases.
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Introduction
Metastases to adrenal gland is common, with usual spread
from melanomas (50%), breast and lung cancers (30-40%), and
renal and gastrointestinal primaries (10-20%).1, 2 Most often,
adrenal metastases are clinically occult due to its rich blood
supply.3 Adrenal enlargement can be appreciated with com-
puted tomography (CT) and/or ultrasonography. Magnetic
resonance imaging and positron emission tomography (PET)
can be helpful in differentiating incidental adrenal adenomas
from small metastases. Historically, the use of radiotherapy
(RT) has been limited to palliation of painful adrenal metas-
tases.4-7 Some recent experience suggested that radiotherapy
might have a survival benefit also.8
Stereotactic body radiotherapy (SBRT) has increasingly been
used to treat primary and metastatic disease outside central
nervous system. Cyberknife, a robotic radiotherapy system
provides unique advantages in terms of frameless non-invasive
treatment, high dose precise delivery and real time tumor
tracking with orthogonal X rays.9 Recent articles especially in
lung and liver malignancies showed benefit in terms of clini-
cal control and non-invasive treatment for surgically declined
groups.10, 11 The similar data in adrenal metastases is still rare.
Here, we present the initial experience of treating adrenal
metastasis with cyberknife fractionated radiotherapy. This is
to the best of our knowledge first ever Indian data reporting
outcomes with Cyberknife fractionated radiotherapy in ad-
renal metastases.
Methods and Materials
We reviewed all the four cases of adrenal metastasis treated at
our center with Cyberknife fractionated radiotherapy till date.
All the cases were healthy males (median age 67 years) with
primary focus of disease in lung for three and renal for one
case. In 2 out of 4 cases, intent of treatment was control of pain
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due to adrenal metastases, while in remaining 2, it was de-
tected as a part of routine follow up screening. Incidentally in
3 cases it was a solitary metastatic deposit in right adrenal
gland only (Table 1). All the metastatic deposit were diag-
nosed on PETCT scan with SUVmax value more than 2.5
taken as positive in an already biopsy proven primary malig-
nancy as per International literature.
TABLE 1: Patient and disease characteristics.
Characteristics Value
Number of patients 4
Gender Male: 4
Age: Range: 49-71 yrs
Median: 67 yrs
Primary site Lung: 3
Kidney: 1




The patients were evaluated through Institutional tumor
board clinic and the options of laparoscopic adrenalectomy
and Cyberknife SBRT were discussed. Patients consented for
non-invasive procedure and hence Cyberknife SBRT was
performed. The emerging data supporting the role of SBRT
also motivated this approach. This was a retrospective review
and hence data collection approval was taken from Institu-
tional review board.
SBRT technique
Cyberknife robotic radiosurgery, an innovative stereotactic
body radiotherapy (SBRT) delivery technique, was used for
treatment in all the cases. Patient immobilization was with
full body vacuum cushion with patient lying supine and both
hands placed above head with an additional custom made
knee rest for pelvic immobilization. Radiotherapy planning
images were acquired in Siemens Biograph 64 slice CT scan-
ner. Planning CT scans of 1 mm thickness were acquired as
per protocol in end expiration and end inspiration phases of
respiration. Planning images were imported in Multiplan
planning system version 4.6.0 (Accuray Incorporated,
Sunnyvale, CA, USA) and after co-registration with additional
contrast and PET-CT scans, targets were delineated with
assistance from an in-house radiologist. Cases were planned
for a median dose of 10 Gy in 2 fractions (range:7-15 Gy) with
75% isodose coverage for targets (Figure 1).
The dose calculation algorithm used was Ray Tracing and grid
size kept at 1 mm. In all the 4 cases, X sight spine tracking was
used for planning and delivery as there was < 3-5 mm spatial
variation of adrenal targets in inspiratory and expiratory
planning scans and the distance from the spinal cord was < 6
cms. The median treatment time was 64 minutes (Table 2).
FIG. 1: Axial CT slice with dose distribution.
FIG. 2: Isodose distribution in Cyberknife plan.
Evaluation of response
Patients were followed up for response assessment and clinical
evaluation. The evaluation of the response was done using the
Response Evaluation Criteria in Solid Tumors (RECIST). The
primary endpoints were post Cyberknife response evaluation
in terms of local and distant survival. Local failure was defined
as progression according to the RECIST criteria.12 Survival and
control times were calculated from the end of Cyberknife
SBRT. All the analyses were done using SPSS version 18.0.
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Since numbers of patients were only four, the basic frequen-
cies were calculated with SPSS and no detail survival analysis
was required.
TABLE 2: Technical features.
Characteristics Value
Adrenal metastasis Size (in cm): Median: 5.1
Range: 3.2-6.5
Pre therapy PETCT SUVmax:
Median: 9.66
Range: 4.7-14.14
Gross tumor volume (GTV) Volume (in cc): Median: 20.5
Range: 3.6-48.8
Dose per fraction Median: 10 Gy
Range: 7-15 Gy
Mean: 10.5 Gy




Prescription isodose Median: 75%
Range: 74-77%
Minimum dose to GTV Median: 23.19 Gy
Range: 12.1 -31.1 Gy
Maximum dose to GTV Median: 32.63 Gy
Range: 18.7 -40.5 Gy
Mean dose to GTV Median: 28.5 Gy
Range: 15.8-36.7 Gy
Treatment time (mins) Median: 64
Range: 54-69
Tracking method X sight spine: 3
Synchrony: 1
Number of beams Range: 181-310
Median: 234
Number of nodes Range: 63-97
Median: 82
Total MU delivered Median: 29284.07
Range: 20045.79-36990.72
Ipsilateral kidney dose Median of mean: 3.9 Gy
Median D20: 5.3 Gy
Median D30: 3.1 Gy
Range of mean dose:2.8-4.0 Gy
Spinal cord dose (max dose)
2cc
Median: 4.6 Gy
Range Dmax: 3.2-6.6 Gy
Range: 1.8-3.2 Gy
PET-CT: Positron emission tomography-computed tomographic scan.
SUV: Standardized uptake value.




The primary sites were lung (n = 3) and renal cell carcinoma (n
= 1). All of them were diagnosed on PETCT scan and the
median gross tumor volume (GTV) was 20.5 cc with a median
size 5.1 cm and on diagnostic PET-CT scans the median SU-
Vmax was 9.66. Patients were taken up for 2 fractions with
median dose per fraction of 10 Gy.
Toxicity
No patient developed acute Radiation Therapy Oncology
(RTOG) Group Grade 2-4 gastrointestinal, hepatic, renal, or
dermatologic toxicity. Mild fatigue was common, as was Grade
1 nausea. Since the median follow up was 6 months no com-
ment could be drawn about late toxicities (Table 3).
TABLE 3: Clinical outcome.
Characteristics Value
Dimension of metastatic disease on
imaging
Pre therapy: Median: 5.1 cm
Range: 3.2 – 6.5 cm
Post therapy: Median: 3.8 cm
Range: 3.3-4.4 cm
Metabolic parameter of metastatic
disease on PETCT
Pre therapy SUVmax: Median:
9.66
Range: 4.7-14.14
Post therapy SUVmax: Medi-
an: 5.5
Range: 4.4-6.6
Post therapy local response CR: 2
PR: 2
Last follow up overall disease status Stable: 1
Distant disease progression: 3
Follow up (FU) duration Range: 4-10 months
Median: 6 months
All 4 patients were alive till
last FU
Dose-volume characteristics
The dose received by the GTV per fraction was between 7-15
Gy per fraction. The minimum, mean and maximum dose
received to GTV was noted and the median value was 23.19,
28.5 and 32.63 Gy respectively. The number of beams used for
planning ranged between 181-310 and median number of
nodes was 82. The median monitor units (MU) delivered was
29284.07.
Ipsilateral kidney and spinal cord were found to be the main
organs at risk. The median of the mean dose received to ipsi-
lateral kidney was 3.9 Gy while median of D20% and D30%
were 5.3 and 3.1 Gy respectively. Similarly the median value
of the dose max to spinal cord was 4.6 Gy (Table 2 and Figure
2).
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FIG. 3: Pre and post Cyberknife imaging for response assessment.
Clinical outcome
Between 8-12 weeks after completion of cyberknife treat-
ment patients were evaluated for imaging based response
assessment with PETCT scan. The timing of PETCT after
SBRT is yet to be validated but most of the SBRT series ad-
vocates between 8-12 weeks although post SBRT changes
may persists for 24 weeks.13 After the therapy median SU-
Vmax on PETCT scan reduced to 5.5 with median tumor size
post therapy being 3.8 cm. As per RECIST criteria 2 patients
had complete morphologic response with no measurable
tumor and no significant SUVmax value and 2 had partial
response (Figure 3). With the median follow up of 6 months,
all the patients were locally controlled and alive. Unfortu-
nately 3 of them had distant disease progression and were on
palliative chemotherapy till last follow up (Table 3).
Discussion
Adrenal gland has been a common site of metastasis specially
from malignancies of lung and kidney.14, 15 In our small series
we had 2 patients diagnosed with adrenal metastasis at
presentation and in other 2 it was detected about a year after
primary disease treatment. The hypothesis behind treating
limited metastatic disease was driven by improved systemic
control after successful local treatment. Furthermore aggres-
sive local control can actually prolong disease free survival.16,
17 Oligometastatic tumors may be amenable to SBRT, in con-
trast to other modalities, especially in circumstances in which
patients do not wish to undergo an invasive procedure or are
in poor general condition.
The Cyberknife robotic radiosurgery system is an innovative
and intelligent tool for SBRT delivery due to couple of rea-
sons. The non-invasive immobilization technique, an inverse
treatment planning technique such that the tumor received
the maximum dose allowable with the restriction of the
maximum normal structure tolerance dose, real time con-
tinuous tracking of the target during treatment with two
ortho-voltage X rays and correction before delivery of
treatment in real time. All this together with short treatment
duration as an outpatient has the potential benefit of better
compliance to treatment. The comorbidities and refusal to
surgery in these patients warrants delivery of radio thera-
peutic ablative dosage as a surgical equivalent. The optimal
management, although still not standardized however a re-
cent systematic review quoted that stereotactic ablative ra-
diotherapy is a valid alternative in cases when surgery is
either refused or not feasible.18
Initially radiotherapy for adrenal metastases was intended for
palliation, to reduce pain symptoms. A study from the Uni-
versity of Pennsylvania retrospectively reviewed 16 patients
treated between 1972 and 1988 with palliative RT for symp-
tomatic adrenal metastases.19 The radiation dose was ranged
from 29.5-45.0 Gy in 2.5-Gy fractions to 30 Gy in 3-Gy frac-
tions. The overall response rate was 75%. Six patients
achieved complete pain relief with durable remission until
death. In a Japanese study, 14 patients, mostly with lung
cancer metastasized to the adrenal glands, received palliative
RT with a dose of 16-60 Gy, fractionated in 1.6-3 Gy/fraction.
The median survival was 3 months, and the 6-month survival
rate was 28.6% for all patients.20
Two recent publications although retrospective, but have
analysed the survival data for adrenal metastases treated by
SBRT. Chawla et al. reported SBRT for 30 patients treated
with a median dose per fraction of 5 Gy, the 1 year survival,
local control and distant control rate of 44%, 55% and 13%
respectively.14 Another study from University of Florence
also highlighted 1 year local control rate of 90% with SBRT
36 Gy in 3 fractions.15 The published data suggests biological
effective dose of greater than 100 Gy for adequate local con-
trol.21
In our preliminary experience all the 4 patients were locally
disease controlled after Cyberknife SBRT and at response
evaluation they had CR or PR. Two patients had abdominal
pain requiring narcotic analgesics prior to treatment, were
actually pain free after Cyberknife SBRT. In accordance to
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world literature patients actually progressed distantly and
developed other new metastatic disease. Here we would
emphasise the role of PETCT in initial diagnosis and response
evaluation. There are plenty of literature available which
established the sensitivity and specificity of PETCT SUVmax
value more than 2.5 in a known malignancy with adrenal
deposit to be metastatic.22, 23 In our small series the minimum
SUVmax value among the four patients was above 4.
The benefits of SBRT with Cyberknife in terms of palliation
of symptoms, better local control irrespective of primary
disease stage or site, non-invasive outpatients department
treatment in a short span with minimal acute effects, defi-
nitely calls for further evaluation. The advent of ablative
radiosurgical dosage achieving similar control rates to surgery
warrants prospective randomized data. The shortcomings of
our study especially in terms of number of patients and short
follow up is well recognized. To the best of our knowledge
first ever data from an Indian center with Cyberknife SBRT
and also among few early world literature, would actually
make path for future clinical trials in treating adrenal metas-
tases with SBRT.
Conclusion
Cyberknife SBRT with its unique advantages can produce
optimal local control for adrenal metastases. The aggressive
nature of the primary disease however can result in poor
overall survival but the non-invasive and surgical equivalent
pain relief and symptom control definitely warrants prospec-
tive data on the routine use of Cyberknife SBRT. Till that
time with the availability of resource and expertise this
modern technique should be used as and when required.
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